Amicus Therapeutics Inc (FOLD)

6.61
0.52 7.30
NASDAQ : Health Care
Prev Close 7.13
Open 7.16
Day Low/High 6.62 / 7.50
52 Wk Low/High 4.98 / 18.83
Volume 3.98M
Avg Volume 2.23M
Exchange NASDAQ
Shares Outstanding 127.05M
Market Cap 805.50M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 Small Biotech Stocks With Big Milestones

As Brexit turmoil calms down, let's get back to small cap stocks.

Commit To Buy Amicus Therapeutics At $3, Earn 18.3% Using Options

Commit To Buy Amicus Therapeutics At $3, Earn 18.3% Using Options

Investors considering a purchase of Amicus Therapeutics Inc stock, but cautious about paying the going market price of $6.02/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 55 cents.

Relative Strength Alert For Amicus Therapeutics

Relative Strength Alert For Amicus Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Amicus Therapeutics Appoints Craig A. Wheeler To Board Of Directors

Amicus Therapeutics Appoints Craig A. Wheeler To Board Of Directors

Re-Elects John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakout trades.

Oversold Conditions For Amicus Therapeutics (FOLD)

Oversold Conditions For Amicus Therapeutics (FOLD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Amicus Shares Barely Budge on Prediction of $3 Billion Buyout

Amicus Shares Barely Budge on Prediction of $3 Billion Buyout

Investors give the side eye to a prediction from Chardan analyst Gbola Amusa that Amicus Therapeutics will be acquired for three times its current market value

Amicus (FOLD) Stock Soars After EU Regulator Recommended Drug

Amicus (FOLD) Stock Soars After EU Regulator Recommended Drug

Amicus (FOLD) stock is surging this afternoon after a European regulator recommended approving the company's Fabry disease treatment.

Amicus Fabry Drug Takes Big Step Toward European Approval

Amicus Fabry Drug Takes Big Step Toward European Approval

A committee of European drug reviewers voted Friday to recommend the approval of the first oral treatment for Fabry disease, developed by Amicus Therapeutics.

6 Biotech Stocks Under $10 to Trade for Big Breakouts

6 Biotech Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

First Week of FOLD May 20th Options Trading

First Week of FOLD May 20th Options Trading

Investors in Amicus Therapeutics Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new May 20th contracts and identified one put and one call contract of particular interest.

Amicus Therapeutics Announces Expanded Access Program For Migalastat

Amicus Therapeutics Announces Expanded Access Program For Migalastat

French National Agency for Medicines and Health Products Safety (ANSM) Grants Temporary Authorization for Use (Cohort ATU) for Patient Sales of Migalastat

7 Breakout Stocks Spiking on Big Volume

7 Breakout Stocks Spiking on Big Volume

These stocks rising on unusual volume are within range of triggering breakout trades.

'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb

'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb

Cramer still believes in Fitbit's long-term outlook but said Amicus Therapeutics is too speculative for him.

Jim Cramer's 'Mad Money' Recap: Commodities Are Healing, so Are Markets

Jim Cramer's 'Mad Money' Recap: Commodities Are Healing, so Are Markets

While many bears are dismissing the rally in commodity stocks as simple short covering, Cramer says there's actually a lot more in play.

First Week of October 21st Options Trading For Amicus Therapeutics (FOLD)

First Week of October 21st Options Trading For Amicus Therapeutics (FOLD)

Investors in Amicus Therapeutics Inc saw new options begin trading this week, for the October 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Amicus Fabry Drug Set for Crucial European Approval Vote

Amicus Fabry Drug Set for Crucial European Approval Vote

A positive opinion on Amicus' migalastat Thursday or Friday will likely lead to the drug's approval in Europe.